Physicians' Academy for Cardiovascular Education

ESC 2020

PACE-CME.org reports news from the digital ESC 2020. Find coverage of the latest CV news on PACE-CME.

No difference in outcomes after 5 years with anti-ischemic metabolic agent in patients after PCI

3' education - Sep. 15, 2020 - Prof. Freek Verheugt

Incredible consistency between two SGLT2i trials in HFrEF

3' education - Sep. 7, 2020 - Milton Packer, MD

No clinical benefit from suspending ACEi/ARBs in hospitalized patients with COVID-19

3' education - Sep. 7, 2020 - Prof. Renato D. Lopes, MD, PhD

Updates in the 2020 AF guidelines

3' education - Sep. 2, 2020 - Prof. Isabelle van Gelder, MD

BP lowering should be considered irrespective of prior CVD or baseline SBP

3' education - Sep. 1, 2020 - Kazem Rahimi, MD

Advantages of the digital 2020 ESC Congress

3' education - Sep. 1, 2020 - Prof. Barbara Casadei, MD

Colchicine reduces primary outcome in chronic coronary disease

3' education - Aug. 31, 2020 - Mark Nidorf, MD

Triage strategy for outpatient management of PE patients based on HESTIA non-inferior to sPESI

5' education - Aug. 31, 2020 - Prof. Menno Huisman, MD

A step ahead in the management of HFmrEF and HFpEF

3' education - Aug. 31, 2020 - Prof. Burkert Pieske, MD

Nephroprotective effects with SGLT2i in CKD patients

3' education - Aug. 30, 2020 - Prof. Hiddo Heerspink, PhD

Huge impact of COVID-19 outbreak on patients with diseases that can normally be treated

3' education - Aug. 30, 2020 - Prof. Barbara Casadei, MD

Aspirin superior to DAPT for bleeding in patients treated with TAVI

3' education - Aug. 30, 2020 - Jorn Brouwer, MD

Succes with SGLT2 inhibitor in HFrEF for all three end points

3' education - Aug. 29, 2020 - Milton Packer, MD

Early rhythm control in AF patients improves outcomes

3' education - Aug. 29, 2020 - Prof. Paulus Kirchhof, MD

Remarkably similar findings with another SGLT2i in HFrEF

3' education - Aug. 29, 2020 - Prof. John McMurray

No difference in outcomes after 5 years with anti-ischemic metabolic agent in patients after PCI

3' education - Sep. 15, 2020 - Prof. Freek Verheugt
Prof. Verheugt briefly discusses the findings of the ATPCI trial, which evaluated the effect of trimetazidine compared to placebo in patients who underwent PCI.

ESC 2020 Prof. Verheugt briefly discusses the findings of the ATPCI trial, which evaluated the effect of trimetazidine compared to placebo in patients who underwent PCI.

Incredible consistency between two SGLT2i trials in HFrEF

3' education - Sep. 7, 2020 - Milton Packer, MD
Although there are differences between the EMPEROR-Reduced and DAPA-HF trials with regard to secondary end points, Milton Packers wants to emphasize the class effects of SGLT2 inhibitors.

ESC 2020 Although there are differences between the EMPEROR-Reduced and DAPA-HF trials with regard to secondary end points, Milton Packers wants to emphasize the class effect of SGLT2 inhibitors.

No clinical benefit from suspending ACEi/ARBs in hospitalized patients with COVID-19

3' education - Sep. 7, 2020 - Prof. Renato D. Lopes, MD, PhD
BRACE CORONA was a randomized trial that tested two strategies in hospitalized patients with COVID-19 who were on ACEi or ARBs: Temporarily suspending or continuing ACEi/ARBs. Prof. Lopes discusses the results.

ESC 2020 BRACE CORONA was a randomized trial that tested two strategies in hospitalized patients with COVID-19 who were on ACEi or ARBs: Temporarily suspending or continuing ACEi/ARBs. Prof. Lopes discusses the results.

Updates in the 2020 AF guidelines

3' education - Sep. 2, 2020 - Prof. Isabelle van Gelder, MD
During the ESC Congress, the 2020 AF guidelines have been presented. Prof. Van Gelder gives an overview of the most important changes.

ESC 2020 During the ESC Congress, the 2020 AF guidelines have been presented. Prof. Van Gelder gives an overview of the most important changes.

P2Y12i alone reduces bleeding in CKD patients after PCI and 3 months DAPT

News - Sep. 2, 2020

ESC 2020 Ticagrelor monotherapy after 3 months DAPT reduced risk of bleeding without increasing rate of thrombotic events compared to ticagrelor plus aspirin in high risk CDK patients undergoing PCI.

BP lowering should be considered irrespective of prior CVD or baseline SBP

3' education - Sep. 1, 2020 - Kazem Rahimi, MD
BP lowering  of 5 mm Hg results in 10% reduction of major CV events and is consistent whether individuals had a previous CVD or not, and is regardless of baseline SBP.

ESC 2020 A study including 48 RCTs demonstrated that lowering of each 5 mmHg SBP resulted in 10% reduction of major CV events, regardless of baseline SBP and CVD status.

Lowering BP reduces risk of major CV events regardless of CVD status and baseline SBP

News - Sep. 1, 2020

ESC 2020 Blood pressure-lowering reduces the risk of major CV events similarly in those with and without CVD and irrespectively of baseline SBP.

Randomized trial on continuing versus suspending ACEi and ARBs in COVID-19

News - Sep. 1, 2020

ESC 2020 Suspension of ACEi/ARB therapy for 30 days did not impact the number of days alive and out of hospital at 30 days compared to continued use of these medications in COVID-19 patients.

Advantages of the digital 2020 ESC Congress

3' education - Sep. 1, 2020 - Prof. Barbara Casadei, MD
Although networking opportunities are poor during this year's ESC congress, there are plusses for a digital congress. Prof. Casadei lists some of them.

ESC 2020 Although networking opportunities are poor during this year's ESC congress, there are plusses for a digital congress. Prof. Casadei lists some of them.

SGLT2i reduces HF hospitalizations in T2DM patients with ASCVD

News - Aug. 31, 2020

ESC 2020 Ertugliflozin reduced time to first HF hospitalization, total HF hospitalizations and total HF hospitalizations/CV death events in T2DM patients with ASCVD.

Combining BMI and polygenic score to predict lifetime risk of diabetes

News - Aug. 31, 2020

ESC 2020 Using data of the UK Biobank, this study showed that BMI and a polygenic score for diabetes have independent and additive effect on lifetime risk of diabetes, and should be used in combination for risk prediction.

Colchicine reduces primary outcome in chronic coronary disease

3' education - Aug. 31, 2020 - Mark Nidorf, MD
Mark Nidorf discusses the results of the LoDoCo2 trial, which evaluated the effects of anti-inflammatory drug colchicine on CV events in patients with coronary artery disease.

ESC 2020 Mark Nidorf discusses the results of the LoDoCo2 trial, which evaluated the effects of the anti-inflammatory drug colchicine on CV events in patients with coronary artery disease.

ESC 2020